MAC-1/2A/2B by simultaneously modelling CTCL and JAK2-translocation neoplasia should be useful tools for preclinical development and assessment of novel targeted therapies. This evidence concerns the gene JAK2 and primary cutaneous T-cell non-Hodgkin lymphoma.